Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

The website changes raise concerns about “the interference of politics with the study and the practice” of science and ...

In this article, we are going to take a look at where Lexicon Pharmaceuticals ... Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind ...

After hours: January 17 at 7:11:27 PM EST ...